- Personalized Cancer Vaccine Mechanism of Action
- Biomarkers Importance In Personalized Vaccines
- Ongoing Clinical Trials on Personalized Cancer Vaccine
- Developmental Cost Analysis of a Personalized Cancer Vaccine
- Immune Checkpoint Biomarkers Preventing Tumor Growth
- Advancements in the Personalized Cancer Vaccine
- Current Market Trends & Advancements in the Personalized Cancer Vaccine Segment
The treatment of cancer through the aspect of using vaccine that has been personalized according to the requirement with an approach that the therapy will provide no harm in the future is innovative yet challenging. The concept of personalized vaccine is recognized as a paradigm shift for the way the cancer is treated and the way cancer is seen in the future. Although many other therapies are available in the present for the treatment of cancer but majority of the therapies come with their own drawbacks and undesirable outcomes.
Personalized vaccine allows us to take a giant step towards the treatment of cancer as in each person's cancer the case is different and the therapy is customized according to the individual cancer scenario. Personalized vaccines when compared with the already existing therapies, has accomplished a great success, with respect to the wide utilization of the treatment in different cancer types. The idea of fitting every cancer patient to the limited drugs has come to an end with the participation of this novel therapeutics into the active field of oncology.
The therapy approaches the development of a neoantigen vaccine that stimulates the immune system to attack the malignant cells in a unique way. Currently, the personalized cancer vaccine of immunotherapy segment is undergoing rapid advancements and improvements with the help of highly skilled researchers at the top universities and laboratories all around the world. Recent research published by some leading science journals reported excellent and emerging outcomes about the cancer vaccines. The current study about the segment is limited to lab animals, but once the testing is over, it will be tested in humans for the first time.
A number of clinical trials regarding the investigational therapy are currently mid-way of becoming the future of the cancer therapies. In the current scenario, USA and Europe are leading the race of having the major market players Increasing adoption to healthcare system and advancements in the genome sequencing techniques are the major contributors to the huge market share in the region.
The research and development of personalized vaccine is supported by both private as well as public sectors by rising their investments in the personalized cancer vaccine segment. The advantage of increasing fundings can provide a valuable option to the patients as well as the research sector. CureVac, Kite pharma, Alphabet, Modema & Merck are some of the major investors in the personalized cancer vaccine segment. The development made by the researchers play an important role in setting up newly available treatments as they will contribute significantly to the cancer treatment and driving the market size by many folds.
The idea behind the development of personalized vaccine is an exception from all the cancer treatments that we all are dependent on. As per report findings, personalized vaccine is successful in showing tremendous progress in the research area and in future it will be a promising approach for treating certain tumors and other inflammatory diseases related with cancer. In the upcoming years, increasing number of cancer patients is expected to increase the market size and revolutionize the entire market for cancer therapies available.
This report on the personalized cancer vaccine market provides a comprehensive insight into the current status of the segment with special emphasis on the clinical innovations governing the market. The report also highlights the clinical relevance of personalized cancer vaccine, trends and recent advances that will impact the growth of the market. Overall, the report concludes with future projections regarding the personalized cancer vaccine segment which shows an exponential growth by 2026.
Table of Contents
1. Personalized Cancer Vaccine: Revolutionizing the Immunotherapeutics of the Future
- 1.1 The Approach Towards Cancer Vaccine Strategy
- 1.2 Cancer Vaccines - Current Clinical Trials Scenario
2. Personalized Cancer Vaccine Mechanism of Action
- 2.1 Entities Involved in Personalized Cancer Vaccine & Their Respective Contributions
- 2.1.1 Tumor Neo - Antigens
- 2.1.2 Human Leukocyte Antigen
- 2.2 General Working of Personalized Cancer Vaccine
- 2.3 Genetic Polymorphism Leading to Pharmacogenomics
- 2.4 Cancer Pharmacogenomics Observing Somatic Mutations
3. Biomarkers Importance In Personalized Vaccines
- 3.1 Pharmacogenomic Biomarkers
- 3.2 Prognostic & Predictive Biomarkers
4. Ongoing Clinical Trials on Personalized Medicines
- 4.1 NEO-PV-01 Showing Glimmers of Success against Melanoma
- 4.2 Personalized Vaccine: An Evolving Biological Discovery for Pancreatic Cancer
- 4.3 Precision Cancer Vaccine against Metastatic Colorectal Cancer
- 4.4 First-in-Human Trial of Personalized Vaccine for Glioblastoma (Brain Tumor)
- 4.5 TG4001 in Combination with Avelumab against HPV Cancers
5. Immune Checkpoint Biomarkers Preventing Tumor Growth
- 5.1 Emerging Biomarkers for CTLA4
- 5.2 PD-1/PD-L1
6. Personalized Cancer Vaccine: Manufacturing Process & Cost Analysis Study
- 6.1 Pre - Manufacturing Cost Analysis
- 6.2 Segmented Cost Analysis of Personalized Cancer Vaccine
- 6.2.1 Capital Cost
- 6.2.2 Cost of Raw Materials
- 6.2.3 Annual Cost of Personnel Involved in Cancer Vaccine Manufacture
- 6.2.4 Factory & Administrative Overheads
- 6.2.5 Filling & Packaging
- 6.3 Per Patient Cost
7. Current Market Trends & Advancements in the Personalized Cancer Vaccine Segment
- 7.1 Researchers Improving the Outcome of Future Personalized Cancer Vaccine
- 7.2 Increasing Investments
- 7.3 Personalized Cancer Vaccine Development using mRNA
- 7.4 Personalized Cancer Vaccine Market Receiving Collaborations & Ventures Ensure Stable Funding
- 7.5 DNA Sequencing Technology Development Driving the Personalized Cancer Vaccine Market
8. Global - Personalized Cancer Vaccine Market Segmentation by Cancer Type
- 8.1 Personalized Cancer Vaccine Breakthrough against Melanoma
- 8.2 Lung Cancer Prevention using Personalized Vaccines
- 8.3 Personalized Cancer Vaccines towards Eliminating Breast Cancer
- 8.4 Colorectal Cancer Eradication by Personalized Cancer Vaccines
- 8.5 Scope of Leukemia Treatment using Personalized Cancer Vaccines
- 8.6 Prostate Cancer Eradication using Personalized Cancer vaccine: Provenge
- 8.7 Personalized Cancer Vaccines Targeting Cervical Cancer
- 8.8 Personalized Cancer Vaccines Application towards Glioblastoma (Brain Tumor)
9. Personalized Cancer Vaccine: Rising with New Avenues & Opportunities
- 9.1 Insights into the Personalized Cancer Vaccine Clinical Pipeline
- 9.2 Opportunities for Personalized Cancer Vaccine in the Emerging Market of the World
10. Porter's Five Force Analysis of the Personalized Cancer Vaccine Market
- 10.1 Bargaining Power of Suppliers
- 10.2 Bargaining Power of Buyer
- 10.3 Threats of Substitute Products
- 10.4 Threat of New Entrants to the already Existing Market
- 10.5 Rivalry Among the Existing Competitors
11. Factors Driving the Market of Personalized Cancer Vaccine
- 11.1 Increased Demand for Personalized Cancer Vaccine Production
- 11.2 Increase Prevalence of Cancer Cases in the Population Worldwide
- 11.3 Cancer Heterogenetic Environment
- 11.4 High Level of Specificity
- 11.5 Assistance from Government
- 11.6 Advancements in Genome Sequencing Techniques Delivering better Personalized Cancer Vaccines
- 11.7 Robust Clinical Pipeline Under Development
12. Challenges Associated with Personalized Cancer Vaccine Market
- 12.1 Scientific & Technical Challenges in Developing a Personalized Cancer Vaccine
- 12.2 Commercial Challenges Surrounding Personalized Cancer Vaccines
13. Global Personalized Cancer Vaccine Market Future Outlook
14. Personalized Medicine Current Market Region Scenario
- 14.1 North America
- 14.2 Latin America
- 14.3 Europe
- 14.4 Asia-Pacific
- 14.4.1 Japan
- 14.4.2 India
- 14.4.3 South Korea
- 14.4.4 Taiwan
- 14.5 Middle East & Africa
15. Global Personalized Vaccine Trends
16. Competitive Landscape
- 16.1 Advaxis Inc.
- 16.2 Avax Technologies
- 16.3 BioNtech AG
- 16.4 Celldex
- 16.5 CureVac AG
- 16.6 Genetech
- 16.7 Genocea
- 16.8 Gristone Oncology
- 16.9 ISA Pharmaceuticals
- 16.10 Merck
- 16.11 Moderna Therapeutics
- 16.12 Neon Therapeutics
- 16.13 Personalis
List of Figures
- Figure 1-1: Cancer Immunotherapeutics in the Development of Cancer Vaccine
- Figure 1-2: Advantages of Targeting Neo - Antigens in Cancer Vaccine Production
- Figure 2-1: Mechanism of Action of a Personalized Cancer Vaccine
- Figure 2-2: Demonstration of Genomic Polymorphism in Pharmacogenomics
- Figure 2-3: The Sources of Pharmacological & Pharmacogenetic Variability's
- Figure 3-1: Illustration of Various Types of Biomarkers in Personalized Medicine
- Figure 3-2: Roadmap of Development of Predictive Biomarkers
- Figure 4-1: Ongoing Clinical Trials on Personalized Vaccines
- Figure 5-1: High Throughput Immune Assessment for Biomarker Discovery
- Figure 6-1: General Overview of Personalized Cancer Vaccine Production
- Figure 6-2: Pre - Manufacturing Cost Analysis for Personalized Cancer Vaccine (US$), 2018
- Figure 6-3: Gardasil - Annualized Capital Cost of Production (US$ Million), 2018
- Figure 6-4: Cervarix - Annualized Capital Cost of Production (US$ Million), 2018
- Figure 6-5: Gardasil - Raw Material Cost Analysis (US$ Million), 2018
- Figure 6-6: Cervarix - Raw Material Cost Analysis (US$ Million), 2018
- Figure 6-7: Gardasil - Annual Cost of Personnel Involved in Cancer Vaccine Manufacture (US$ Million), 2018
- Figure 6-8: Cervarix - Annual Cost of Personnel Involved in Cancer Vaccine Manufacture (US$ Million), 2018
- Figure 6-9: Gardasil - Factory & Administrative Overheads (US$ Million), 2018
- Figure 6-10: Cervarix - Factory & Administrative Overheads (US$ Million), 2018
- Figure 6-11: Gardasil - Manufacturing Cost per single Dose (US$), 2018
- Figure 6-12: Cervarix - Manufacturing Cost per single Dose (US$), 2018
- Figure 6-13: Personalized Cancer Vaccine - Treatment Cost (US$/Patient), 2018
- Figure 6-14: Global - HPV Vaccine Adoption Rate by Regions (%), 2018
- Figure 6-15: Gardasil & Gardasil 9 - Cost Analysis (US$), October' 2019
- Figure 7-1: Trends & Advancement in the Personalized Cancer Vaccine Segment
- Figure 7-2: Investments Generated by Key Market Players in the Personalized Cancer Segment (US$ Million), 2018
- Figure 8-1: Alteration in CDKN2A Mechanism
- Figure 8-2: Global - Melanoma & Non - Melanoma Cancer Incidence (000'), 2018
- Figure 8-3: Global - Melanoma Prevalence by Region (%), 2018
- Figure 8-4: Global - Lung Cancer Incidence & Deaths (Million), 2018
- Figure 8-5: Global - Lung Cancer Prevalence by Region (%), 2018
- Figure 8-6: Global - Breast Cancer Incidence & Deaths (Million), 2018
- Figure 8-7: Global - Breast Prevalence by Region (%), 2018
- Figure 8-8: Global - Colorectal Cancer Incidence & Deaths (Million), 2018
- Figure 8-9: Global - Colorectal Cancer Market Size (%), 2018
- Figure 8-10: Global - Leukemia Incidence (000'), 2018
- Figure 8-11: Global - Leukemia Market Size (%), 2018
- Figure 8-12: Global - Prostate Cancer Incidence (000'), 2018
- Figure 8-13: Global - Prostate Cancer Prevalence by Region (%), 2018
- Figure 8-14: Provenge - Cost Analysis (US$/Month)
- Figure 8-15: Global - Cervical Cancer Incidence (000'), 2018
- Figure 8-16: Global - Cervical Cancer prevalence by Region (%), 2018
- Figure 9-1: Global - Oncology Market Size by Region (%), 2017
- Figure 10-1: Porter's Five Force Analysis - Overview
- Figure 11-1: Driving Factors of the Personalized Cancer Vaccine Market
- Figure 11-2: Global - Most Common Types of Cancer by Prevalence, 2018
- Figure 11-3: Decrease in the Cost of Human Genome Sequencing (US$/Patient), 2018
- Figure 11-4: Time Taken in Whole Genome Sequencing (Months/Patient), 2018
- Figure 12-1: Scientific Limitations in Personalized Cancer Vaccine Development
- Figure 13-1: Global - Gardasil/ Gardasil 9 Sales (US$ Billion), 2018 -2026
- Figure 13-2: Gardasil/ Gardasil 9 Sales - US v/s Rest of World (US$ Billion), 2018
- Figure 13-3: Gardasil/ Gardasil 9 - Global Patent Insight
- Figure 13-4: Global - Personalized Cancer Vaccine Market Opportunity (US$ Billion), 2019 - 2026
- Figure 14-1: US - Total Cancer Deaths, 2016 - 2018
- Figure 14-2: Europe - Total Cancer Deaths, 2016 - 2018
- Figure 14-3: Asia-Pacific - Total Cancer Deaths, 2018
- Figure 14-4: Japan - Total Cancer Deaths, 2016 & 2018
- Figure 14-5: India - Total Cancer Deaths, 2014 & 2018
- Figure 14-6: South Korea - Total Cancer Deaths, 2014 - 2016
- Figure 14-7: Taiwan - Total Cancer Deaths, 2017 - 2018
List of Tables
- Table 8-1:Illustration of Targetable Oncogenic Drivers in Non-Small Lung Cancer
- Table 8-2: Personalized Strategies to Attain Target in Acute Myeloid Leukemia
